Similarly, in high-risk neuroblastoma, SETD8 augments the proliferative capacity of tumor cells and confers resistance to apoptosis through the epigenetic silencing of the tumor protein p53 [13]; and it inhibits ferroptosis in pancreatic cancer cells through the downregulation of the RRAD [15]. Here, TP53 is linked to neuroblastoma.